Covid-19 roundup: Sino­vac shot com­plete­ly pre­vents se­vere cas­es at 14-day mark, com­pa­ny says

Sino­vac has made some big da­ta claims on its way to a ten­ta­tive ap­proval in Chi­na for its Covid-19 vac­cine. New Phase III da­ta show promis­ing re­sults in pre­vent­ing se­vere dis­ease, but will it be enough to con­vince in­ter­na­tion­al reg­u­la­tors?

Phase III tri­als of the vac­cine, al­so called Coro­n­aVac, be­gan back in Ju­ly and were on­go­ing in Brazil, Turkey, In­done­sia and Chile us­ing a 0/14 day sched­ule with a to­tal en­roll­ment of 25,000 par­tic­i­pants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER